Alcon Inc
Company Profile
Business description
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Contact
Chemin de Blandonnet 8
Royce Bedward
Vernier
Geneva1214
CHET: +41 589112110
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2024
Employees
25,315
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
stocks
Is this overpriced ASX share too much of a gamble?
stocks
ASX players that might thrive under a Trump administration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,539.00 | 59.10 | 0.70% |
| CAC 40 | 7,311.80 | 94.97 | 1.32% |
| DAX 40 | 19,263.70 | 260.59 | 1.37% |
| Dow JONES (US) | 43,750.86 | 207.33 | -0.47% |
| FTSE 100 | 8,071.19 | 40.86 | 0.51% |
| HKSE | 19,546.70 | 110.89 | 0.57% |
| NASDAQ | 19,107.65 | 123.07 | -0.64% |
| Nikkei 225 | 38,749.97 | 214.27 | 0.56% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,949.17 | 36.21 | -0.60% |
| S&P/ASX 200 | 8,285.20 | 61.20 | 0.74% |
| SSE Composite Index | 3,363.35 | 16.49 | -0.49% |